GlobeNewswire Inc.··NaFulcrum's Pociredir Shows Strong Hemoglobin Gains in Sickle Cell Phase 1b Trial
Fulcrum's pociredir shows strong fetal hemoglobin gains in sickle cell Phase 1b trial, with 58% of patients reaching therapeutic levels and reduced pain crises.
FULCrare diseaseclinical trial results